- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04283097
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects With Hematological Malignancies
This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels.
Indication: Hematological malignancies (multiple myeloma [MM], mantle cell lymphoma [MCL], diffuse large B-cell lymphoma [DLBCL], adult T-cell leukemia-lymphoma [ATL], and indolent non Hodgkin lymphomas such as follicular lymphoma [FL] and chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL]).
Study Overview
Detailed Description
This will be a dose escalation study in subjects with selected hematological malignancies. KPG-818 will be used in combination with dexamethasone in subjects with MM, and as monotherapy for other selected hematological malignancies. Each dose of KPG-818 will be administered orally until the completion of treatment cycles, or progressive disease (PD), unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met.
The highest dose level which may be tested is 5 mg KPG-818 and dose levels 2, 3, 4, and 5 mg and/or intermediate dosing or alternative dosing schedule may be explored. Each dose level (1-4) will be tested using the standard 3+3 design. DLT will be assessed during the DLT evaluation period (Cycle 1) and the treatment of study is divided into 6 cycles.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Kai Wei, MD
- Phone Number: +8618201496205
- Email: kai.wei@kangpugroup.com
Study Contact Backup
- Name: Yao Wang, MD
- Phone Number: +19738738678
- Email: yao.wang@kangpugroup.com
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- UC Davis Comprehensive Cancer Center
-
Contact:
- Aaron Rosenberg
-
-
Florida
-
Plantation, Florida, United States, 33322
- Recruiting
- BRCR Global - USA
-
Contact:
- Harshad Amin
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Completed
- Norton Cancer Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48202-2689
- Recruiting
- Henry Ford Health System - Hemophilia and Thrombosis Treatment Center
-
Contact:
- Ahmad Mattour
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Recruiting
- Mohamad Medical Cherry
-
Contact:
- Mohamad M Cherry
-
-
North Carolina
-
Durham, North Carolina, United States, 27710-4000
- Recruiting
- Duke University Health System - Duke Endoscopy - Duke Clinic 2H
-
Contact:
- Christiana Costa Chase
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Completed
- Providence Portland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- Recruiting
- Upmc Cancercenter
-
Contact:
- Jing-Zhou Hou
-
-
Texas
-
Laredo, Texas, United States, 78041
- Recruiting
- Laguna Clinical Research Associates
-
Contact:
- Eduardo Miranda
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226-0509
- Active, not recruiting
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥ 18 years of age
- Willing and able to provide written consent.
- Willing and able to adhere to the study visit schedule and other protocol requirements.
- Hematocytological or pathological diagnosis of MM, MCL, DLBCL, ATL, indolent lymphoma, such as FL and CLL/SLL, etc.
- Subjects who have relapsed from or are refractory to MM, MCL, DLBCL, ATL, indolent lymphoma, such as FL and CLL/SLL.
- Have measurable or assessable disease.
- Meet the laboratory requirements:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Males and females of childbearing potential must agree to use at least two methods of contraception and continue until 3 months after the completion of study treatment.
Exclusion Criteria:
- Has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
- Currently enrolled in another clinical study, except observational studies.
- Has known active central nervous system metastases and/or lymphomatous meningitis.
- Persisting toxicities related to prior anticancer treatment > Grade 1.
- Major surgery or significant traumatic injury within 6 weeks prior to Screening or planned major surgery during the study period.
- Received live attenuated vaccine within 4 weeks of first dose.
- Subjects with gastrointestinal disease that may significantly alter the absorption of the study drug.
- Subjects with a plasma cell leukemia.
- Subjects with prior history of malignancies, other than MM, lymphoma, or CLL/SLL, unless the subject has been free of the disease for ≥ 5 years.
- Has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, or pomalidomide.
- Has known or suspected hypersensitivity to the excipients contained in the formulation of investigational product (IP).
- Has been treated with an investigational agent (i.e., an agent not commercially available) within 28 days of initiating IP.
- Prior treatment of any inhibitors of PD-1 or PD-L1 within 3 months prior to initiating IP.
Has any one of the following:
- Clinically significant abnormal ECG finding at Screening.
- Congestive heart failure.
- Myocardial infarction within 12 months prior to initiating IP.
- Unstable or poorly controlled angina pectoris, including the Prinzmetal variant of angina pectoris.
- Peripheral neuropathy ≥ Grade 2.
- Subject has taken a strong inhibitor or inducer of CYP3A4/5 including grapefruit, St. John's Wort or related products within 2 weeks prior to dosing and during the course of study.
- Has current or prior use of immunosuppressive medication within 14 days prior initiating IP.
- Subject known to test positive for human immunodeficiency virus, active hepatitis B, or active hepatitis C.
- Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.
- Subject is a female who is pregnant, nursing, or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
KPG-818 dose escalation
|
The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg.
Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met.
The treatment of study is divided into 6 cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: Up to 6 months of treatment
|
Number of Treatment-Emergent Adverse Events(TEAE), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and changes from baseline in laboratory parameters, vital signs, and ECG.
|
Up to 6 months of treatment
|
Recommended Phase 2 Dose (RP2D)
Time Frame: Up to 4 weeks of treatment
|
Maximum tolerated dose defined as the highest dose level at which 33% or less subjects experience DLT as defined by the protocol.
|
Up to 4 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK profile of KPG-818: maximum observed plasma concentration (Cmax).
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
PK profile of KPG-818: time of the maximum observed plasma concentration (Tmax)
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
PK profile of KPG-818: area under the plasma concentration-time profile (AUC) from time zero to the last quantifiable concentration (AUC0-t).
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
PK profile of KPG-818: AUC from time zero extrapolated to infinity (AUC0-∞).
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
PK profile of KPG-818: AUC within a dosing interval (AUC0-τ).
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
PK profile of KPG-818: apparent total plasma clearance (CL/F).
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
PK profile of KPG-818: apparent total plasma clearance at steady-state (CLss/F).
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
PK profile of KPG-818: apparent volume of distribution (Vz/F)
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
PK profile of KPG-818: apparent volume of distribution at steady-state (Vss).
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
PK profile of KPG-818: apparent plasma terminal elimination. half-life (t1/2)
Time Frame: Up to 4 weeks of treatment
|
Up to 4 weeks of treatment
|
|
Assessment of clinical activity: objective response rate (ORR).
Time Frame: Up to 6 months of treatment
|
Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL).
|
Up to 6 months of treatment
|
Assessment of clinical activity: disease control rate (DCR).
Time Frame: Up to 6 months of treatment
|
Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL).
|
Up to 6 months of treatment
|
Assessment of clinical activity: time to response, duration of response.
Time Frame: Up to 6 months of treatment
|
Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL).
|
Up to 6 months of treatment
|
Assessment of clinical activity: progression-free survival.
Time Frame: Up to 6 months of treatment
|
Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL).
|
Up to 6 months of treatment
|
Assessment of clinical activity: event-free survival (EFS), and transplantation rate (TR).
Time Frame: Up to 6 months of treatment
|
Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL).
|
Up to 6 months of treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers of KPG-818
Time Frame: Up to 6 months of treatment
|
Aiolos and Ikaros in peripheral blood mononuclear cell (PBMC)
|
Up to 6 months of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: MD, Kangpu Biopharmacuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KPG-818-HEM-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancies
-
Tel-Aviv Sourasky Medical CenterMeir Medical Center; Max Planck Institute for Infection BiologyUnknownPediatric Solid Malignancies | Pediatric Hematological MalignanciesIsrael
-
AdaptimmuneTerminatedSolid and Hematological MalignanciesUnited States, Canada
-
Senti BiosciencesNot yet recruitingAML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological Malignancies
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory Hematological MalignanciesChina
-
AdaptimmuneRecruitingSolid and Hematological MalignanciesUnited States, Spain, Canada, United Kingdom
-
Kite, A Gilead CompanyEnrolling by invitationSolid and Hematological MalignanciesUnited States, Netherlands, Japan, Australia, France, Israel, Germany, Canada, United Kingdom
-
AstraZenecaParexelCompletedSolid and Hematological MalignanciesGermany
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineCompletedMyeloid Hematological MalignanciesUnited States
-
Centre Hospitalier Universitaire de BesanconTerminatedHematological Malignancies BFrance
-
CASI Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada
Clinical Trials on KPG-818
-
Kangpu Biopharmaceuticals, Ltd.Active, not recruiting
-
Kangpu Biopharmaceuticals, Ltd.CompletedSystemic Lupus ErythematosusUnited States
-
TaiRx, Inc.CompletedCarcinoma | Advanced CancerTaiwan
-
M.D. Anderson Cancer CenterRecruitingMetastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8United States
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
TaiRx, Inc.CompletedCarcinoma | Advanced CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedMetastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent Pancreatic Carcinoma | Locally Advanced Pancreatic CarcinomaUnited States
-
Corvus Pharmaceuticals, Inc.Active, not recruitingT-cell LymphomaUnited States, China, Australia, Korea, Republic of
-
TaiRx, Inc.CompletedAdvanced CancerTaiwan
-
Providence Health & ServicesRecruitingBRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...United States